Durham, North Carolina — According to state and local economic development sources CARsgen Therapeutics plans to invest $157,000,000.00 to build out 137,000 square feet of new space in Durham. The company plans to occupy the new space in Durham, on or about December 1, 2022. According to the company website We are a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. Since our inception in 2014, We have internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors and reducing treatment costs. Our product pipeline include an upgraded fully-human BCMA CAR-T (CT053), globally potential first-in-class Claudin18.2 CAR-T (CT041) with the only IND clearance, and globally potential first-in-class GPC3 CAR-T (CT011). we had obtained seven IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China.

To learn more about CARsgen Therapeutics, visit http://www.carsgen.com/

Company Contact:
Zonghai Li, Chief Executive Officer
zonghaili@carsgen.com
https://www.linkedin.com/in/zonghai-li-17226630/
346-293-9392

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved